Parrish Capital LLC decreased its holdings in Astrazeneca Plc (NYSE:AZN – Free Report) by 55.0% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 11,555 shares of the company’s stock after selling 14,111 shares during the quarter. Astrazeneca accounts for about 2.0% of Parrish Capital LLC’s investment portfolio, making the stock its 8th largest position. Parrish Capital LLC’s holdings in Astrazeneca were worth $2,279,000 at the end of the most recent quarter.
Other large investors also recently added to or reduced their stakes in the company. Natixis Advisors LLC increased its position in Astrazeneca by 14.3% in the third quarter. Natixis Advisors LLC now owns 2,100,390 shares of the company’s stock worth $161,142,000 after buying an additional 262,465 shares in the last quarter. Guardian Capital LP raised its stake in shares of Astrazeneca by 31.0% in the third quarter. Guardian Capital LP now owns 83,074 shares of the company’s stock worth $6,373,000 after buying an additional 19,648 shares during the period. Legacy Capital Group California Inc. bought a new position in shares of Astrazeneca in the third quarter worth about $406,000. Focus Partners Advisor Solutions LLC lifted its position in shares of Astrazeneca by 53.8% during the 3rd quarter. Focus Partners Advisor Solutions LLC now owns 10,307 shares of the company’s stock valued at $875,000 after buying an additional 3,604 shares in the last quarter. Finally, Integral Health Asset Management LLC lifted its position in shares of Astrazeneca by 50.0% during the 3rd quarter. Integral Health Asset Management LLC now owns 300,000 shares of the company’s stock valued at $23,016,000 after buying an additional 100,000 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Several research firms recently issued reports on AZN. Wall Street Zen raised shares of Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Astrazeneca in a report on Tuesday, June 30th. TD Cowen reiterated a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Astrazeneca in a research note on Tuesday, June 30th. Finally, Morgan Stanley restated an “overweight” rating on shares of Astrazeneca in a research report on Wednesday, April 8th. Fourteen investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $205.33.
Astrazeneca Price Performance
Shares of NYSE:AZN opened at $194.96 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91. The firm has a fifty day moving average price of $183.96 and a 200 day moving average price of $188.09. Astrazeneca Plc has a fifty-two week low of $137.23 and a fifty-two week high of $212.71. The firm has a market cap of $302.36 billion, a price-to-earnings ratio of 29.27, a P/E/G ratio of 1.58 and a beta of 0.24.
Astrazeneca (NYSE:AZN – Get Free Report) last posted its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.52 by $0.06. The company had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. As a group, sell-side analysts expect that Astrazeneca Plc will post 10.28 earnings per share for the current fiscal year.
About Astrazeneca
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
Read More
- Five stocks we like better than Astrazeneca
- These Stocks Could Win as Wall Street Looks Beyond AI Software
- D.R. Horton Is Defying the Housing Gloom
- Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire
- Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
